Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment Market to Witness CAGR of 6.3% during 2018– 2024: Energias Market Research Pvt. Ltd.
23 mars 2018 07h00 HE
|
Energias Market Research
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment market size is expected to reach, USD 153.5 Billion in 2024, at a CAGR of 6.3% from 2018...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
12 mai 2015 05h08 HE
|
Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...
![Rafarma Pharmaceuticals, Inc. logo](/news-release/logo/258442/0/258442.jpg?lastModified=12%2F10%2F2016%2000%3A29%3A48&size=2)
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
06 juin 2013 09h18 HE
|
Rafarma Pharmaceuticals, Inc.
SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.
Ceftriaxone treats...